35290 Search Results


alternative collection numbers cbs 352 90  (ATCC)
93
ATCC alternative collection numbers cbs 352 90
Alternative Collection Numbers Cbs 352 90, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/alternative collection numbers cbs 352 90/product/ATCC
Average 93 stars, based on 1 article reviews
alternative collection numbers cbs 352 90 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
recombinant rat sdf 1α cxcl12  (R&D Systems)
91
R&D Systems recombinant rat sdf 1α cxcl12
Recombinant Rat Sdf 1α Cxcl12, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant rat sdf 1α cxcl12/product/R&D Systems
Average 91 stars, based on 1 article reviews
recombinant rat sdf 1α cxcl12 - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier
shrna plasmid  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology shrna plasmid
<t>UMUC3-control-shRNA</t> A. or UMUC3-AR-shRNA B. treated with ethanol (mock) or 1 nM DHT for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR of NFAT , NKX2–5 <t>,</t> <t>ELK1</t> , ROR , GLI1 , and MyoD . Expression of each gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . mock treatment). ** P < 0.01 ( vs . mock treatment).
Shrna Plasmid, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shrna plasmid/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
shrna plasmid - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
elk1 sirna1  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology elk1 sirna1
<t>UMUC3-control-shRNA</t> A. or UMUC3-AR-shRNA B. treated with ethanol (mock) or 1 nM DHT for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR of NFAT , NKX2–5 <t>,</t> <t>ELK1</t> , ROR , GLI1 , and MyoD . Expression of each gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . mock treatment). ** P < 0.01 ( vs . mock treatment).
Elk1 Sirna1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elk1 sirna1/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
elk1 sirna1 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
pbba6c rfp  (Addgene inc)
93
Addgene inc pbba6c rfp
<t>UMUC3-control-shRNA</t> A. or UMUC3-AR-shRNA B. treated with ethanol (mock) or 1 nM DHT for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR of NFAT , NKX2–5 <t>,</t> <t>ELK1</t> , ROR , GLI1 , and MyoD . Expression of each gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . mock treatment). ** P < 0.01 ( vs . mock treatment).
Pbba6c Rfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbba6c rfp/product/Addgene inc
Average 93 stars, based on 1 article reviews
pbba6c rfp - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
elk 1 h 20  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology elk 1 h 20
<t>UMUC3-control-shRNA</t> A. or UMUC3-AR-shRNA B. treated with ethanol (mock) or 1 nM DHT for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR of NFAT , NKX2–5 <t>,</t> <t>ELK1</t> , ROR , GLI1 , and MyoD . Expression of each gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . mock treatment). ** P < 0.01 ( vs . mock treatment).
Elk 1 H 20, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elk 1 h 20/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
elk 1 h 20 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
ammonium chloride  (Chem Impex International)
96
Chem Impex International ammonium chloride
<t>UMUC3-control-shRNA</t> A. or UMUC3-AR-shRNA B. treated with ethanol (mock) or 1 nM DHT for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR of NFAT , NKX2–5 <t>,</t> <t>ELK1</t> , ROR , GLI1 , and MyoD . Expression of each gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . mock treatment). ** P < 0.01 ( vs . mock treatment).
Ammonium Chloride, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ammonium chloride/product/Chem Impex International
Average 96 stars, based on 1 article reviews
ammonium chloride - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


UMUC3-control-shRNA A. or UMUC3-AR-shRNA B. treated with ethanol (mock) or 1 nM DHT for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR of NFAT , NKX2–5 , ELK1 , ROR , GLI1 , and MyoD . Expression of each gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . mock treatment). ** P < 0.01 ( vs . mock treatment).

Journal: Oncotarget

Article Title: ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression

doi:

Figure Lengend Snippet: UMUC3-control-shRNA A. or UMUC3-AR-shRNA B. treated with ethanol (mock) or 1 nM DHT for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR of NFAT , NKX2–5 , ELK1 , ROR , GLI1 , and MyoD . Expression of each gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . mock treatment). ** P < 0.01 ( vs . mock treatment).

Article Snippet: A shRNA plasmid targeting human ELK1 (sc-35290-SH; Santa Cruz Biotechnology) or a non-silencing control shRNA plasmid (sc-108060; Santa Cruz Biotechnology) was transfected, using Lipofectamine ® 2000 transfection reagent (Life Technologies).

Techniques: Control, shRNA, RNA Extraction, Quantitative RT-PCR, Expressing

A. Quantitative RT-PCR of ELK1 . UMUC3-control-shRNA/AR-shRNA and 647V-AR/control treated with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR. Expression of ELK1 gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. Western blotting of ELK1 in UMUC3 and 647V-AR treated with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours. Total protein extracted from each cell line B. or separate nuclear and cytoplasmic protein fractions C. were immunoblotted for ELK1 (62 kDa). Histone H1 (32–33 kDa) and GAPDH (37 kDa) served as internal controls of nuclear and cytoplasmic proteins, respectively. D. Immunofluorescent staining of ELK1 in UMUC3 treated with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours. We merged the images between ELK1 and DAPI that was used to visualize nuclei. Cytoplasmic signals of ELK1 are seen in mock- or DHT+HF-treated cells, but not in DHT-treated cell. E. ELK1 luciferase reporter activity in UMUC3 and 647V-AR transfected with pELK1-Luc and pRL-TK and subsequently cultured with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours. Luciferase activity is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. F. Quantitative RT-PCR of c-fos . UMUC3-control/AR-shRNA and 647V-AR/control treated with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR. Expression of ELK1 gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . mock treatment). ** P < 0.01 ( vs . mock treatment). *** P < 0.001 ( vs . mock treatment).

Journal: Oncotarget

Article Title: ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression

doi:

Figure Lengend Snippet: A. Quantitative RT-PCR of ELK1 . UMUC3-control-shRNA/AR-shRNA and 647V-AR/control treated with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR. Expression of ELK1 gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. Western blotting of ELK1 in UMUC3 and 647V-AR treated with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours. Total protein extracted from each cell line B. or separate nuclear and cytoplasmic protein fractions C. were immunoblotted for ELK1 (62 kDa). Histone H1 (32–33 kDa) and GAPDH (37 kDa) served as internal controls of nuclear and cytoplasmic proteins, respectively. D. Immunofluorescent staining of ELK1 in UMUC3 treated with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours. We merged the images between ELK1 and DAPI that was used to visualize nuclei. Cytoplasmic signals of ELK1 are seen in mock- or DHT+HF-treated cells, but not in DHT-treated cell. E. ELK1 luciferase reporter activity in UMUC3 and 647V-AR transfected with pELK1-Luc and pRL-TK and subsequently cultured with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours. Luciferase activity is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. F. Quantitative RT-PCR of c-fos . UMUC3-control/AR-shRNA and 647V-AR/control treated with ethanol (mock), 1 nM DHT, and/or 5 μM HF for 24 hours were subjected to RNA extraction and subsequent real-time RT-PCR. Expression of ELK1 gene was normalized to that of GAPDH . Transcription amount is presented relative to that of mock treatment in each cell line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . mock treatment). ** P < 0.01 ( vs . mock treatment). *** P < 0.001 ( vs . mock treatment).

Article Snippet: A shRNA plasmid targeting human ELK1 (sc-35290-SH; Santa Cruz Biotechnology) or a non-silencing control shRNA plasmid (sc-108060; Santa Cruz Biotechnology) was transfected, using Lipofectamine ® 2000 transfection reagent (Life Technologies).

Techniques: Quantitative RT-PCR, Control, shRNA, RNA Extraction, Expressing, Western Blot, Staining, Luciferase, Activity Assay, Transfection, Cell Culture

A. Quantitative RT-PCR of ELK1 in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. Expression of ELK1 gene was normalized to that of GAPDH. Transcription amount is presented relative to that of control-shRNA expression in each cell line. Each value represents the mean (+SD) from at least three independent experiments. B. Western blotting of ELK1 in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. Cell extracts were immunoblotted for ELK1 (62 kDa). GAPDH (37 kDa) served as an internal control. C. ELK1 luciferase reporter activity in UMUC3 transfected with pELK1-Luc, pRL-TK, and control- or ELK1-shRNA. Luciferase activity is presented relative to that of control-shRNA expression. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . control-shRNA). ** P < 0.01 ( vs . control-shRNA).

Journal: Oncotarget

Article Title: ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression

doi:

Figure Lengend Snippet: A. Quantitative RT-PCR of ELK1 in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. Expression of ELK1 gene was normalized to that of GAPDH. Transcription amount is presented relative to that of control-shRNA expression in each cell line. Each value represents the mean (+SD) from at least three independent experiments. B. Western blotting of ELK1 in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. Cell extracts were immunoblotted for ELK1 (62 kDa). GAPDH (37 kDa) served as an internal control. C. ELK1 luciferase reporter activity in UMUC3 transfected with pELK1-Luc, pRL-TK, and control- or ELK1-shRNA. Luciferase activity is presented relative to that of control-shRNA expression. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . control-shRNA). ** P < 0.01 ( vs . control-shRNA).

Article Snippet: A shRNA plasmid targeting human ELK1 (sc-35290-SH; Santa Cruz Biotechnology) or a non-silencing control shRNA plasmid (sc-108060; Santa Cruz Biotechnology) was transfected, using Lipofectamine ® 2000 transfection reagent (Life Technologies).

Techniques: Quantitative RT-PCR, Control, shRNA, Expressing, Western Blot, Luciferase, Activity Assay, Transfection

A. MTT assay in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA cultured for 1–5 days. Cell viability is presented relative to that of each control line at day 1. Each value represents the mean (+SD) from at least three independent experiments. B. Clonogenic assay in UMUC3-control-shRNA/ELK1-shRNA cultured for 2 weeks. The number of colonies and their areas quantitated, using the ImageJ software, are presented relative to those of each control line. Each value represents the mean (+SD) from at least three independent experiments. TUNEL assay C. and flow cytometry D. in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. Apoptosis is presented relative to that of each control line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . control-shRNA). ** P < 0.01 ( vs . control-shRNA). *** P < 0.001 ( vs . control-shRNA).

Journal: Oncotarget

Article Title: ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression

doi:

Figure Lengend Snippet: A. MTT assay in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA cultured for 1–5 days. Cell viability is presented relative to that of each control line at day 1. Each value represents the mean (+SD) from at least three independent experiments. B. Clonogenic assay in UMUC3-control-shRNA/ELK1-shRNA cultured for 2 weeks. The number of colonies and their areas quantitated, using the ImageJ software, are presented relative to those of each control line. Each value represents the mean (+SD) from at least three independent experiments. TUNEL assay C. and flow cytometry D. in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. Apoptosis is presented relative to that of each control line. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 ( vs . control-shRNA). ** P < 0.01 ( vs . control-shRNA). *** P < 0.001 ( vs . control-shRNA).

Article Snippet: A shRNA plasmid targeting human ELK1 (sc-35290-SH; Santa Cruz Biotechnology) or a non-silencing control shRNA plasmid (sc-108060; Santa Cruz Biotechnology) was transfected, using Lipofectamine ® 2000 transfection reagent (Life Technologies).

Techniques: MTT Assay, Control, shRNA, Cell Culture, Clonogenic Assay, Software, TUNEL Assay, Flow Cytometry

A. Wound healing assay in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. The cells grown to confluence were gently scratched and the wound area was measured after 24-hour culture. The migration determined by the rate of cells filling the wound area is presented relative to that of each control line. Each value represents the mean (+SD) from at least three independent experiments. B. Transwell invasion assay in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA cultured in the Matrigel-coated transwell chamber. The number of invaded cells present in the lower chamber was counted under a light microscope (100x objective in five random fields). Cell invasion is presented relative to that of each control line. Each value represents the mean (+SD) from three independent experiments. C. Quantitative RT-PCR of MMP-2 and MMP-9 in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. Expression of each specific gene was normalized to that of GAPDH . Transcription amount is presented relative to that of each control line. Each value represents the mean (+SD) from at least three independent experiments. D. Gelatin zymography in UMUC3-control-shRNA/ELK1-shRNA. The activity of MMP-2 or MMP-9 was indicated by clear zones of gelatin lysis against a blue background of stained substrate. * P < 0.05 ( vs . control-shRNA). ** P < 0.01 ( vs . control-shRNA). *** P < 0.001 ( vs . control-shRNA).

Journal: Oncotarget

Article Title: ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression

doi:

Figure Lengend Snippet: A. Wound healing assay in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. The cells grown to confluence were gently scratched and the wound area was measured after 24-hour culture. The migration determined by the rate of cells filling the wound area is presented relative to that of each control line. Each value represents the mean (+SD) from at least three independent experiments. B. Transwell invasion assay in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA cultured in the Matrigel-coated transwell chamber. The number of invaded cells present in the lower chamber was counted under a light microscope (100x objective in five random fields). Cell invasion is presented relative to that of each control line. Each value represents the mean (+SD) from three independent experiments. C. Quantitative RT-PCR of MMP-2 and MMP-9 in UMUC3-control-shRNA/ELK1-shRNA and 647V-AR-control-shRNA/ELK1-shRNA. Expression of each specific gene was normalized to that of GAPDH . Transcription amount is presented relative to that of each control line. Each value represents the mean (+SD) from at least three independent experiments. D. Gelatin zymography in UMUC3-control-shRNA/ELK1-shRNA. The activity of MMP-2 or MMP-9 was indicated by clear zones of gelatin lysis against a blue background of stained substrate. * P < 0.05 ( vs . control-shRNA). ** P < 0.01 ( vs . control-shRNA). *** P < 0.001 ( vs . control-shRNA).

Article Snippet: A shRNA plasmid targeting human ELK1 (sc-35290-SH; Santa Cruz Biotechnology) or a non-silencing control shRNA plasmid (sc-108060; Santa Cruz Biotechnology) was transfected, using Lipofectamine ® 2000 transfection reagent (Life Technologies).

Techniques: Wound Healing Assay, Control, shRNA, Migration, Transwell Invasion Assay, Cell Culture, Light Microscopy, Quantitative RT-PCR, Expressing, Zymography, Activity Assay, Lysis, Staining

MTT assay in UMUC3-control-shRNA/ELK1-shRNA cultured for 5 days in the presence of ethanol (mock) or 1 nM DHT A. or in 647V-control-shRNA/ELK1-shRNA cultured for 5 days B. Cell viability is presented relative to that of mock-treated control line (A, lane 1) or that of control line (B) Each value represents the mean (+SD) from at least three independent experiments. Wound healing assay in UMUC3-control-shRNA/ELK1-shRNA in the presence of ethanol (mock) or 1 nM DHT C. in 647V-control-shRNA/ELK1-shRNA D. The cells grown to confluence were gently scratched and the wound area was measured after 24-hour culture. The migration determined by the rate of cells filling the wound area is presented relative to that of mock-treated control line (C, lane 1) or that of control line (D) Each value represents the mean (+SD) from at least three independent experiments. E. ELK1 luciferase reporter activity in UMUC3-control-shRNA and UMUC3-ELK1-shRNA transfected with pELK1-Luc and pRL-TK and subsequently cultured in the presence of ethanol (mock) or 1 nM DHT. Luciferase activity is presented relative to that of each line with mock treatment. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 (mock vs . DHT in each line). ** P < 0.01 (mock vs . DHT in each line). # P < 0.05 (control- vs . ELK1-shRNA lines with DHT). ## P < 0.01 (control- vs . ELK1-shRNA lines with DHT). + P < 0.05 (control- vs . ELK1-shRNA lines with mock treatment). □□ P < 0.01 (control- vs . ELK1-shRNA lines).

Journal: Oncotarget

Article Title: ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression

doi:

Figure Lengend Snippet: MTT assay in UMUC3-control-shRNA/ELK1-shRNA cultured for 5 days in the presence of ethanol (mock) or 1 nM DHT A. or in 647V-control-shRNA/ELK1-shRNA cultured for 5 days B. Cell viability is presented relative to that of mock-treated control line (A, lane 1) or that of control line (B) Each value represents the mean (+SD) from at least three independent experiments. Wound healing assay in UMUC3-control-shRNA/ELK1-shRNA in the presence of ethanol (mock) or 1 nM DHT C. in 647V-control-shRNA/ELK1-shRNA D. The cells grown to confluence were gently scratched and the wound area was measured after 24-hour culture. The migration determined by the rate of cells filling the wound area is presented relative to that of mock-treated control line (C, lane 1) or that of control line (D) Each value represents the mean (+SD) from at least three independent experiments. E. ELK1 luciferase reporter activity in UMUC3-control-shRNA and UMUC3-ELK1-shRNA transfected with pELK1-Luc and pRL-TK and subsequently cultured in the presence of ethanol (mock) or 1 nM DHT. Luciferase activity is presented relative to that of each line with mock treatment. Each value represents the mean (+SD) from at least three independent experiments. * P < 0.05 (mock vs . DHT in each line). ** P < 0.01 (mock vs . DHT in each line). # P < 0.05 (control- vs . ELK1-shRNA lines with DHT). ## P < 0.01 (control- vs . ELK1-shRNA lines with DHT). + P < 0.05 (control- vs . ELK1-shRNA lines with mock treatment). □□ P < 0.01 (control- vs . ELK1-shRNA lines).

Article Snippet: A shRNA plasmid targeting human ELK1 (sc-35290-SH; Santa Cruz Biotechnology) or a non-silencing control shRNA plasmid (sc-108060; Santa Cruz Biotechnology) was transfected, using Lipofectamine ® 2000 transfection reagent (Life Technologies).

Techniques: MTT Assay, Control, shRNA, Cell Culture, Wound Healing Assay, Migration, Luciferase, Activity Assay, Transfection

A. UMUC3-control-shRNA/ELK1-shRNA cells were implanted subcutaneously into the left/right flanks of NOD-SCID mice, respectively, and tumor formation and its growth were monitored. B. Kaplan-Meier curves and log-rank test according to the endpoint set as tumor volume exceeding 40 mm 3 . C. Tumor size (estimated volume of each tumor exceeded 40 mm 3 at day 0) was subsequently monitored every day. Each value represents the mean (+SD or –SD).

Journal: Oncotarget

Article Title: ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression

doi:

Figure Lengend Snippet: A. UMUC3-control-shRNA/ELK1-shRNA cells were implanted subcutaneously into the left/right flanks of NOD-SCID mice, respectively, and tumor formation and its growth were monitored. B. Kaplan-Meier curves and log-rank test according to the endpoint set as tumor volume exceeding 40 mm 3 . C. Tumor size (estimated volume of each tumor exceeded 40 mm 3 at day 0) was subsequently monitored every day. Each value represents the mean (+SD or –SD).

Article Snippet: A shRNA plasmid targeting human ELK1 (sc-35290-SH; Santa Cruz Biotechnology) or a non-silencing control shRNA plasmid (sc-108060; Santa Cruz Biotechnology) was transfected, using Lipofectamine ® 2000 transfection reagent (Life Technologies).

Techniques: Control, shRNA